Head-to-head evidence
albuterol HFA (Proventil HFA) vs Ventolin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol HFA (Proventil HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
In this trial, Proventil-HFA is the established reference product that the investigational Armstrong's albuterol-HFA is being compared against, rather than the agent under primary evaluation itself, and no results have been posted yet.
Ventolin
Developed by GlaxoSmithKline
NCT01076322 · Phase 3 · completed
The study randomized participants to treatment sequences and included Ventolin as the active comparator, but it was open-label and small, with an estimated 17 participants. Its primary endpoint, change in FEV1, is a clinical lung-function measure, but no results are posted to show whether the comparison was favorable for Ventolin or met its prespecified objective.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol HFA (Proventil HFA)'s landscape · Ventolin's landscape